Immutep (NASDAQ:IMMP) Stock Passes Below Fifty Day Moving Average – Time to Sell?

Immutep Limited (NASDAQ:IMMP)’s stock price passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.92 and traded as low as $1.88. Immutep shares last traded at $1.88, with a volume of 56,504 shares traded.

Immutep Stock Performance

The company has a 50 day moving average price of $1.92 and a 200 day moving average price of $2.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.25 and a current ratio of 18.25.

Institutional Investors Weigh In On Immutep

Several institutional investors have recently modified their holdings of IMMP. Fortitude Advisory Group L.L.C. purchased a new stake in shares of Immutep during the 4th quarter worth approximately $28,000. OLD Mission Capital LLC purchased a new stake in shares of Immutep during the 4th quarter worth approximately $36,000. Two Sigma Securities LLC purchased a new stake in shares of Immutep during the 4th quarter worth approximately $74,000. ABC Arbitrage SA purchased a new stake in Immutep in the 4th quarter valued at approximately $152,000. Finally, XY Capital Ltd lifted its stake in Immutep by 52.0% in the 4th quarter. XY Capital Ltd now owns 164,655 shares of the biotechnology company’s stock valued at $357,000 after buying an additional 56,306 shares in the last quarter. Hedge funds and other institutional investors own 2.32% of the company’s stock.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.